ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Acumen Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Comment by M101on Jul 12, 2021 4:25pm

106 Views

Post# 33530968

RE:Acumen Pharmaceuticals Inc

Thanks for the reminder.

Their website is just a token but there is enough published on ACU-3B3 to identify where ACU-193 is headed.
https://www.nature.com/articles/s41598-018-22979-2

This single data point of IPO valuation is far more relevant to Promis than all the aducanumab spin. Competent management would be commenting to shareholders on this and the theory behind it, and sooner than later!

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth